Effects of trimetazidine on cardiac function in adult cyanotic congenital heart disease patients: Protocol for a 3-month multicenter, randomized, double-blind controlled trial
Study context
- Population
- Adults with cyanotic congenital heart disease (CCHD)planned
- Participants
- 80 adults
- Planned comparison
- Trimetazidine vs placebo
- Primary endpoint
- Change in ejection fractions (EF) measured by cardiac MRI from baseline
- Follow-up
- 3 months
Methodological detailsprotocol, double-blind, placebo-controlled, multicentre
- Protocol
- Double-blind
- Placebo-controlled
- Multicentre
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Effects of trimetazidine on cardiac function in adult cyanotic congenital heart disease patients: Protocol for a 3-month multicenter, randomized, double-blind controlled trial. Am Heart J. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →